GM Pharmaceuticals launches regionally centric line of allergy and cold products in Texas
ARLINGTON, Texas — GM Pharmaceuticals on Wednesday announced the launch of TexaClear, a new liquid allergy, sinus, cough-cold and flu line, made by Texans for Texans. The TexaClear line will hit the shelves of H-E-B stores on Nov. 10.
According to the company, every year Texans suffer from what is commonly known as “Cedar Fever.” Despite its name, “Cedar Fever” is actually caused by the pollen of ashe juniper, a small evergreen tree that is located in Central Texas anywhere between the Red River and the Rio Grande.
Right in time for the peak of Texas allergy season, TexaClear has the only liquid anti-inflammatory pain reliever for sinus, cough-cold and flu symptoms. The line includes TexaClear Allergy Relief, Sinus Relief and Cough, Cold and Flu Relief for both daytime and nighttime.
Ohio Governor’s Council on People with Disabilities names Kroger ‘Employer of the Year’
CINCINNATI — Kroger announced Friday it has been named "Employer of the Year" by the Ohio Governor's Council on People with Disabilities for significantly contributing to employment opportunities for individuals with disabilities.
Kroger was nominated for this recognition by the Warren County Board of Developmental Disabilities. The company received the award at a ceremony at the Ohio Statehouse on Oct. 16.
"We have a long tradition of hiring people with disabilities, especially on our front lines serving customers," stated Keith Dailey, Kroger's director of corporate communications. "Kroger is honored to receive this recognition from the Governor's Council on People with Disabilities and the Warren County Board of Developmental Disabilities."
Kroger also was recognized earlier this year by the Marriott Foundation for People with Disabilities. Kroger has worked with the Marriott Foundation's Bridges from School to Work program to help transition young people with disabilities from high school to the workforce.
GPhA: Health Affairs blog ‘confirms central role that generic drugs play in lowering healthcare costs’
WASHINGTON — In the wake of an Oct. 21 blogpost on Health Affairs, “The $500 Billion Medicare Slowdown: A Story About Part D,” Ralph Neas, president and CEO of the Generic Pharmacuetical Association, issued the following statement.
The article "confirms the central role that generic drugs have played in lowering healthcare costs in Medicare," Neas wrote. He continued, "According to the authors, ‘Lower Part D spending primarily stems from the 'patent cliff' — a number of blockbuster brand-name drugs that have lost patent protection, paving the way for cheaper generic competitors…’ This new analysis follows a recent report by the Office of the Actuary at the Centers for Medicare and Medicaid Services, which noted in January 2014 that reduced growth rates for prescription drug spending were driven largely by a slowdown in overall prices paid for medicines as generic versions became available for costly brand drugs.
"GPhA and its member companies will continue to prioritize efforts that increase and expedite access to lower cost medicines. Generic medicines are critical to a sustainable healthcare system and the generic drug industry is unwavering in its commitment to delivering safe, more affordable generic medicines to patients who need them.
"Further, we look forward to the next frontier of affordable medicines, biosimilars, which will create billions in additional savings. In fact, a recent study by Express Scripts estimates that over 10 years, the United States would save $250 billion if just the 11 likeliest biosimilars would enter the market.”
Loading Post Please Wait...